

# CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)



*CCLM* is the official journal of the Association of Clinical Biochemists in Ireland (ACBI), the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC), the German United Society for Clinical Chemistry and Laboratory Medicine (DGKL), the Hungarian Society of Laboratory Medicine (MLDT), the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC), the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine (SPML), the Slovenian Association for Clinical Chemistry and Laboratory Medicine (SZKKLM), and the Turkish Biochemical Society (TBD). *CCLM* is affiliated with the Australasian Association of Clinical Biochemists (AACB) and the Royal Belgian Society of Laboratory Medicine (RBSLM).

## EDITOR-IN-CHIEF

*Mario Plebani*  
Padova, Italy

## ASSOCIATE EDITORS

*Giuseppe Lippi*  
Reviews Editor  
Verona, Italy  
*Philippe Gillary*  
Reims, France  
*Karl J. Lackner*  
Mainz, Germany  
*Bohuslav Melichar*  
Olomouc, Czech Republic  
*Peter Schlattmann*  
Jena, Germany  
*Jill R. Tate*  
Brisbane, Australia  
*Gregory J. Tsongalis*  
Lebanon, USA

## EFLM LIAISON

*Ana-Maria Simundic*  
Zagreb, Croatia

## EDITORIAL BOARD

*Rossa Wai Kwun Chiu*  
Hong Kong, China  
*Sail Chun*  
Seoul, Korea  
*Eleftherios P. Diamandis*  
Toronto, Canada  
*Arnold von Eckardstein*  
Zurich, Switzerland  
*Rajiv T. Erasmus*  
Stellenbosch, South Africa  
*Emmanuel Favaloro*  
Westmead, Australia  
*Juan M. Guerrero*  
Seville, Spain  
*João Tiago Guimaraes*  
Porto, Portugal  
*Markus Herrmann*  
Bolzano, Italy  
*Johannes J.M.L. Hoffmann*  
Nuenen, Netherlands  
*Kiyoshi Ichihara*  
Ube, Japan  
*Berend Isermann*  
Magdeburg, Germany

## Petr Jarolim

Boston, USA  
*János Kappelmayer*  
Debrecen, Hungary  
*Steven Kazmierczak*  
Portland, USA  
*Wolfgang Korte*  
St. Gallen, Switzerland  
*Christos Kroupis*  
Athens, Greece  
*Leslie Charles Lai*  
Kuala Lumpur, Malaysia  
*Sylvain Lehmann*  
Montpellier, France  
*Janja Marc*  
Ljubljana, Slovenia  
*David Meyre*  
Hamilton, Canada  
*Tomris Özben*  
Antalya, Turkey  
*Vladimir Palicka*  
Hradec Králové,  
Czech Republic  
*Mauro Panteghini*  
Milan, Italy

## Maria Pasic

Toronto, Canada  
*Geraldo Picheth*  
Curitiba, Brazil  
*Gérard Siest*  
Nancy, France  
*Grazyna Sypniewska*  
Bydgoszcz, Poland  
*Kannan Vaidynathan*  
Tiruvalla, India  
*Oswald Wagner*  
Vienna, Austria  
*Pierre Wallemacq*  
Brussels, Belgium  
*John B. Whitfield*  
Brisbane, Australia  
*Shengkai Yan*  
Beijing, China  
*Ian S. Young*  
Belfast, UK

## MANAGING EDITOR

*Heike Jahnke*  
Berlin, Germany

**ABSTRACTED/INDEXED IN** Academic Search; Advanced Placement Source; Analytical Abstracts; Baidu Scholar; BIOBASE/CABS (Current Awareness in Biological Sciences); Biological Abstracts; BIOSIS Previews; CAB Abstracts; Celdes; Chemical Abstracts Service (CAS); Chemical Abstracts Service (CAS) - SciFinder; CNKI Scholar (China National Knowledge Infrastructure); CNPIEC; Current Contents/Life Sciences; Deep Indexing: Science Journals; Discovery Service (EBSCO); EMBASE; Gale/Cengage; Global Health; Google Scholar; ICAP Alcohol Information Databases; Illustrata: Natural Sciences; Illustrata: Technology; J-Gate; Journal Citation Reports/Science Edition; JournalTOCs; Materials Research Database; Medline; MegaFILE; Naviga (Softweco); Neurosciences Abstracts; Primo Central (ExLibris); Prous Science Integrity; PubMed; PubHub; ReadCube; ResearchGate; Science Citation Index; Science Citation Index Expanded; Sciencescape; SCImago (SJR); SCOPUS; Summon (Serials Solutions/ProQuest); TDOne (TDNet); Technology Research Database; TEMA Technik und Management; TOC Premier; Ulrich's Periodicals Directory/ulrichsweb; WorldCat (OCLC).

*CCLM* is the official journal of the Association of Clinical Biochemists in Ireland (ACBI), the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC), the German United Society for Clinical Chemistry and Laboratory Medicine (DGKL), the Hungarian Society of Laboratory Medicine (MLDT), the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC), the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine (SPML), the Slovenian Association for Clinical Chemistry and Laboratory Medicine (SZKKLM), and the Turkish Biochemical Society (TBD). *CCLM* is affiliated with the Australasian Association of Clinical Biochemists (AACB) and the Royal Belgian Society of Laboratory Medicine (RBSLM).

The publisher, together with the authors and editors, has taken great pains to ensure that all information presented in this work (programs, applications, amounts, dosages, etc.) reflects the standard of knowledge at the time of publication. Despite careful manuscript preparation and proof correction, errors can nevertheless occur. Authors, editors and publisher disclaim all responsibility for any errors or omissions or liability for the results obtained from use of the information, or parts thereof, contained in this work.

The citation of registered names, trade names, trademarks, etc. in this work does not imply, even in the absence of a specific statement, that such names are exempt from laws and regulations protecting trademarks etc. and therefore free for general use.

ISSN 1434-6621 · e-ISSN 1437-4331 · CODEN CCLMFW

All information regarding notes for contributors, subscriptions, Open access, back volumes and orders is available online at [www.degruyter.com/cclm](http://www.degruyter.com/cclm).

**RESPONSIBLE EDITOR(S)** Prof. Dr. Mario Plebani, Università di Padova, Dipartimento di Medicina di Laboratorio, Azienda Ospedaliera di Padova, Via Nicolo Giustiniani 2, 35131 Padova, Italy. Tel.: +390 (0)49 821 2792, Fax: +390 (0)49 663 240, Email: [mario.plebani@unipd.it](mailto:mario.plebani@unipd.it)

**JOURNAL MANAGER** Heike Jahnke, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany, Tel.: +49 (0)30 260 05 – 220, Fax: +49 (0)30 260 05 – 325, Email: [heike.jahnke@degruyter.com](mailto:heike.jahnke@degruyter.com)

**RESPONSIBLE FOR ADVERTISEMENTS** Claudia Neumann, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany. Tel.: +49 (0)30 260 05-226, Fax: +49 (0) 30 260 05-264, Email: [anzeigen@degruyter.com](mailto:anzeigen@degruyter.com)

© 2016 Walter de Gruyter GmbH, Berlin/Boston

**TYPESETTING** Compuscript Ltd., Shannon, Ireland

**PRINTING** Franz X. Stückle Druck und Verlag e.K., Ettenheim

Printed in Germany

**COVER ILLUSTRATION** Research lab © Eisenhans. Permission to use the image on the cover granted by Fotolia LLC.



## Contents

### Special issue: Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies

Guest Editors: Jillian R. Tate, Maria Stella Graziani, Peter Mollee and Giampaolo Merlini

#### Editorial

Jillian R. Tate, Maria Stella Graziani, Peter Mollee and Giampaolo Merlini

**Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies — 899**

#### Laboratory Testing as Recommended by the Guidelines and the International Myeloma Working Group

Maria A.V. Willrich and Jerry A. Katzmann

**Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias — 907**

Peter Mollee and Giampaolo Merlini

**Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis — 921**

Nelson Leung, David R. Barnidge and Colin A. Hutchison  
**Laboratory testing in monoclonal gammopathy of renal significance (MGRS) — 929**

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Bassetti, Francesca Russo, Tiziana Bosoni, Laura Pirolini, Veronica Valentini, Giovanni Ferraro, Francesca Lavatelli, Alessandra Barassi, Riccardo Albertini and Giampaolo Merlini

**The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis — 939**

#### Serum and Urine Protein Electrophoresis and Immunofixation Testing

David F. Keren and Lee Schroeder

**Challenges of measuring monoclonal proteins in serum — 947**

Carel J. Pretorius

**Screening immunofixation should replace protein electrophoresis as the initial investigation of monoclonal gammopathy: Point — 963**

Joel D. Smith, Geoffrey Raines and Hans G. Schneider  
**Should routine laboratories stop doing screening serum protein electrophoresis and replace it with screening immune-fixation electrophoresis? No quick fixes: Counterpoint — 967**

Michael A. Moss

**Moving towards harmonized reporting of serum and urine protein electrophoresis — 973**

Peter Sečník, Jr., Eva Honsová, Antonín Jabor, Petra Lavříková and Janka Franeková

**Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis — 981**

Robyn Henry and Debra Glegg

**Use of isoelectric focusing to discriminate transient oligoclonal bands from monoclonal protein in treated myeloma — 985**

Anna Caldini, Chiara Nozzoli, Alessandro Terreni, Michela Staderini, Margherita Berardi, Tiziana Biagioli, Marco Brogi and Alberto Bosi

**New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation — 991**

#### Serum Free Light Chain Methods and Controversies

Hugh D. Carr-Smith, Ellen L. Jenner, Josie A.R. Evans and Stephen J. Harding

**Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents — 997**

Henk te Velthuis, Mark Drayson and John P. Campbell  
**Measurement of free light chains with assays based on monoclonal antibodies — 1005**

Maria Stella Graziani  
**Measurement of free light chains – pros and cons of current methods — 1015**

Joannes F.M. Jacobs, Jillian R. Tate and Giampaolo Merlini  
**Is accuracy of serum free light chain measurement achievable? — 1021**

Charlotte Toftmann Hansen  
**Performance goals for immunoglobulins and serum free light chain measurements in plasma cell dyscrasias can be based on biological variation — 1031**

Paolo Milani, Veronica Valentini, Giovanni Ferraro, Marco Bassetti, Francesca Russo, Andrea Foli, Giovanni Palladini and Giampaolo Merlini  
**A patient with AL amyloidosis with negative free light chain results — 1035**

Stanley S. Levinson  
**Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease — 1039**

Alice Kennard, Carmel Hawley, Jill Tate, Sandra Klingberg, Carel Pretorius, Colin Hutchison and Peter Mollee  
**Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis — 1045**

## New Laboratory Assays and Challenges

Josie A.R. Evans, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding  
**Quantification of β-region IgA monoclonal proteins – should we include immunochemical Hevylite® measurements? Point — 1053**

Lucia Paolini  
**Quantification of β region IgA paraproteins – should we include immunochemical “heavy/light chain” measurements? Counterpoint — 1059**

Sara Altinier, Kozeta Proko, Martina Zaninotto, Daniela Ciubotaru, Mara Seguso, Mariacristina Varagnolo, Federica Lessi, Chiara Briani, Fausto Adami and Mario Plebani

**Free light chains and heavy/light chains in monitoring POEMS patients — 1065**

David R. Barnidge, Angela Dispenzieri, Giampaolo Merlini, Jerry A. Katzmann and David L. Murray  
**Monitoring free light chains in serum using mass spectrometry — 1073**

Maria Alice V. Willrich, Paula M. Ladwig, Bruna D. Andreguetto, David R. Barnidge, David L. Murray, Jerry A. Katzmann and Melissa R. Snyder  
**Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation — 1085**

Christopher McCudden, Amy E. Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schechter, Tahamtan Ahmadi and A. Kate Sasser  
**Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference — 1095**

Niels W.C.J. van de Donk, Henny G. Otten, Omar El Haddad, Amy Axel, A. Kate Sasser, Sandra Croockewit and Joannes F.M. Jacobs  
**Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) — 1105**

## Letter to the Editor

Laura Caponi, Maria Franzini, Elona Koni, Silvia Masotti, Mario Petrini and Aldo Paolicchi  
**Discrepancy between FLC assays: only a problem of quantification? — 1111**